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Abstract
Mouse models have been developed to investigate colorectal cancer etiology and evaluate new anti-cancer therapies. While
genetically engineered and carcinogen-induced mouse models have provided important information with regard to the
mechanisms underlying the oncogenic process, tumor xenograft models remain the standard for the evaluation of new
chemotherapy and targeted drug treatments for clinical use. However, it remains unclear to what extent explanted
colorectal tumor tissues retain inherent pathological features over time. In this study, we have generated a panel of 27
patient-derived colorectal cancer explants (PDCCEs) by direct transplantation of human colorectal cancer tissues into NOD-
SCID mice. Using this panel, we performed a comparison of histology, gene expression and mutation status between
PDCCEs and the original human tissues from which they were derived. Our findings demonstrate that PDCCEs maintain key
histological features, basic gene expression patterns and KRAS/BRAF mutation status through multiple passages. Altogether,
these findings suggest that PDCCEs maintain similarity to the patient tumor from which they are derived and may have the
potential to serve as a reliable preclinical model that can be incorporated into future strategies to optimize individual
therapy for patients with colorectal cancer.
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Introduction
Colorectal cancer (CRC) is the third most common cancer and
the second leading cause of cancer death in the United States. In
2010, approximately 142,000 people were diagnosed with CRC,
and about 40% of these patients presented with advanced disease
[1]. Treatment for advanced CRC with chemotherapy is typically
intended for disease control and palliation of symptoms only, and
as a result, unresectable CRC remains an incurable disease. In
order to improve clinical outcomes and develop new therapeutic
approaches, the development of a reliable preclinical model to
study CRC biology and drug sensitivities is required.
Mouse models of CRC remain one of the most useful tools to
decipher the biological mechanisms underlying the oncogenic
process. To date, a variety of genetically-engineered, carcinogen-
induced and xenograft mouse models have been established [2,3]
and it is generally agreed that no one model is sufficient to
elucidate all aspects of CRC etiology.
Genetically engineered mouse (GEM) models have been
invaluable in establishing the role of many different genetic
mutations and signal transduction pathways contributing to the
oncogenic process and allow investigation in the context of an
active immune system [2,3]. However, many of these GEM
models, primarily those involving mutation of the APC tumor
suppressor gene, develop tumors in the small intestine rather than
the colon. This makes longitudinal disease progression studies
difficult in addition to lacking the genetic complexity observed in
human cancers [2,3].
Another widely used mouse models of CRC relies on the use of
carcinogens to induce colorectal tumor development. Perhaps the
most widely used carcinogen-based model is the Azoxymethane
(AOM) model. Here, colorectal tumor development is initiated by
AOM, a potent, colon-specific carcinogen through the formation
of DNA adducts [4]. Colorectal tumors derived using this model
recapitulate key human pathological features observed in humans
and allow investigation of the early stages of CRC. However
tumor initiation and development is a time consuming process,
often taking up to 6 months with tumor multiplicity and
penetrance depending heavily on the mouse strain [2,5,6].
While GEM and carcinogen-based models have significantly
enhanced our knowledge of the genetics and etiology of CRC,
these models do not allow for accurate testing of cancer
therapeutics to be used in the clinical setting [7]. The most widely
utilized in vivo model for the testing of anti-cancer drug efficacy and
combinations is the xenograft model. Historically, xenografts have
been established through the subcutaneous injection of genetically-
defined human-derived cell lines into immune-compromised nude
mice [8]. However, to date, the majority of these cell line-based
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translates into clinically relevant information [7]. In addition,
recent reports suggest that tumor-stroma interactions not present
in cell line-based xenografts may represent an integral component
in oncogenic potential and tumor drug response [9,10]. Therefore,
more recently, whole-tissue explants derived from human cancers
including breast [11], lung [12], prostate [13] and colorectal
cancer [14–16] have been established in an attempt to generate
more clinically accurate and reliable xenograft models. However,
these studies examined mainly early passage explants (,5
generations) from predominantly primary tumors and therefore
there remains the need to further characterize these models and
evaluate how well they retain important characteristics of the
original human tumor especially in metastatic disease.
In this study, we have performed a more comprehensive
molecular and histological analysis of a panel of 27 matched
patient-derived colorectal cancer explants (PDCCEs) from both
primary and metastatic sites as an extension of our previous work
[17] in which we compared the gene expression profile of 14
matched PDCCEs and their corresponding human tumors. We
now demonstrate that PDCCEs retain global gene expression
patterns, oncogene mutation status and histological parameters
present in the original human cancers. Altogether these findings
suggest that PDCCEs have the potential to serve as a reliable
preclinical model that can be used to develop and characterize
new therapeutic targets for patients with CRC.
Materials and Methods
Tumor Samples/Ethics Statement
A total of 27 human samples were obtained for genomic and
histological analysis. All patients provided written consent to have
tissue stored and used for research. Samples used for analysis in
the laboratory were de-identified and not linked with any personal
health information (PHI). All parts of this study were approved by
the Duke Institutional Review Board. All animal studies were
performed under a Duke University Institutional Animal Care and
Use Committee (IACUC) approved protocol.
Generation of Patient-Derived Colorectal Cancer Explants
(PDCCEs)
Colorectal tumors (both primary and metastatic) at time of
surgery were collected under a Duke IRB approved protocol
(Pro00002435). The tissues were washed with phosphate buffered
saline (PBS) and then minced into pieces approximately ,2m m
in size and injected into the flanks of 4-week-old NOD.CB17-
PrkdcSCID-J mice obtained from Jackson Laboratories under
a Duke IACUC approved protocol. Mice were observed and
tumors measured with vernier calipers until the volume of the
tumor ((V=L62W60.52 (L = longest diameter, W = shortest
diameter)) reached ,1,000 mm
3. Tumors were then harvested,
minced and re-implanted as described above until stable PDCCEs
were established. At each generation, tumors were harvested and
either fixed in 10% neutral buffered formalin (NBF), snap frozen
in liquid nitrogen or frozen in optimal cutting temperature (OCT)
medium on dry ice for further analysis.
Histological Preparation and Examination
Paraffin-embedded PDCCE tissues were sectioned in 6 mm
intervals and stained with hemotoxylin and eosin (H&E). Each
sample was evaluated by a trained pathologist for the following
histological criteria: histologic type, CDX-2 positivity, and relative
percentage of tumor, necrosis, stroma, tumor gland formation and
CDX-2 positive nuclei. All tissues were examined using .10 high-
powered fields per section. Tumor nuclei were evaluated for
CDX-2 staining using a standard quantitative scale of 0, 1+,2 +
and 3+. Staining of tumor nuclei at 2+ and 3+ was considered
positive and all cases considered positive exhibited at least 20% of
tumor nuclei with staining.
Oncogene Mutation Analysis
Genomic DNA was isolated from snap frozen PDCCE tissues
using a Qiagen genomic DNA isolation kit. Samples were diluted
to 10 ng/ml and PCR was performed using the following primers
for KRAS: forward 59 GTGTGACATGTTCTAATATAGTCA
39; reverse 59 GAATGGTCCTGCACCAGTAA 39 and BRAF:
forward 59 TCATAATGCTTGCTCTGATAGGA 39; reverse 59
GGCCAAAAATTTAATCAGTGGA 39. Amplicons were se-
quenced by conventional methods using the forward primers.
Microarray Analysis
RNA was isolated from snap-frozen PDCCE tissues using
a Qiagen RNA/DNA Allprep kit, converted to cDNA and labeled
by one cycle IVT. IVT labeled cDNAs were prepared according
to the manufacturer’s instructions, and targets hybridized to the
Human U133A 2.0 GeneChip and read on an Affymetrix array
scanner. Raw data was converted to. CEL files and RMA
Table 1. Sites from which PDCCEs were derived.





























Preclinical Model of Colorectal Cancer
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38422normalized. CEL files (GSE35144) are available at the Gene
Expression Omnibus (GEO) data repository (http://www.ncbi.
nlm.nih.gov/geo/). To check for sample outliers and batch effects,
3D principal components analysis of the global gene expression
was performed. Batch effects were normalized using the ComBat
algorithm (http://jlab.byu.edu/ComBat/) [18]. Unsupervised
hierarchical clustering of the human tumors and matching
PDCCEs was performed on the 20% of genes with the greatest
coefficient of variation. Agglomerative clusters were generated
using the pearson correlation coefficient and complete linkage
using the R program (The R Foundation for Statistical
Computing).
Software Used for Analysis
The R statistical software package is available at www.r-project.
org. The Bioconductor R package is available at www.
bioconductor.org. ComBat is available as an R script at http://
jlab.byu.edu/ComBat/. Graphpad Prism is a product of Graph-
pad Software (La Jolla, CA, USA) and is available at www.
graphpad.com/prism/prism.htm.
Results
Histological Evaluation of PDCCEs
A panel of 27 patient-derived colorectal cancer explants
(PDCCEs) by direct transplantation of human colorectal cancer
(CRC) tissues into NOD-SCID mice was created in this study.
Table 1 shows the origin of the patient tumor and a total of 5
primary PDCCEs and 22 metastatic PDCCEs were generated. To
assess the extent to which in vivo models of patient-derived
colorectal cancer explants (PDCEEs) accurately recapitulate and
can therefore serve as a model of the human condition, we
investigated whether PDCCEs retain key biological features
inherent to individual human colorectal cancers (CRC) over time.
First, to evaluate the extent to which histological parameters are
retained after xeno-transplantation, two independent PDCCEs
were passaged through .10 generations and evaluated histolog-
Figure 1. PDCCE tumor pathology is retained after 11 generations in mice. H&E stained sections of two independent well-differentiated
adenocarcinomas (CRC039 and CRC075) show that tumor architecture remains similar after 11 passages in NOD/SCID mice. Images shown are at 206
magnification.
doi:10.1371/journal.pone.0038422.g001
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remarkably consistent with the original patient tumor through 11
generations (Figure 1). Next, a comprehensive histological
evaluation performed on a sub-panel of 15 matched PDCCEs
and original banked tissues revealed that 15/15 PDCCEs retained
pathological features similar to those observed in the matched
human tumor and were characterized as histologically identical to
their matched original banked sample (Table 2). Even after 11
generations, PDCCEs retained the ability to form glands and
contained CDX-2 positive nuclei comparable to the first
generation PDCCEs (Figure 2). These data demonstrate that the
histological features present in colorectal cancer, including the
formation of glands and presence of stromal components are
retained even in late passage explants, suggesting that unlike CRC
cell line-derived xenografts, the PDCCE model provides us with
a research tool that recapitulates the human condition generally
not observed in other models.
PDCCEs Retain Basic Global Gene Expression Profiles
Inherent to Human Colorectal Cancers
Next, to further evaluate the extent to which PDCCEs represent
their primary human counterparts, we analyzed 27 matched
patient tumors and PDCCEs by microarray analysis. Patient
tumor and PDCCE gene expression data was first normalized
Table 2. Histological comparison of patient tumor and PDCCEs.
Sample ID Source Generation %Tumor %Necrosis %Stroma
%Tumor Gland
Formation Histologic Type
CRC008 Patient 65 5 25 80 Adenocarcinoma, NOS
PDCCE 3rd 70 10 20 70 Adenocarcinoma, NOS
CRC028 Patient 10 80 10 40 Adenocarcinoma w/signet ring
PDCCE 1st 25 5 70 40 Adenocarcinoma w/signet ring
CRC034 Patient 65 0 35 80 Adenocarcinoma, NOS
PDCCE 1st 85 5 10 75 Adenocarcinoma, NOS
CRC039 Patient 10 0 90 50 Adenocarcinoma w/mucinous
PDCCE 1st 60 0 40 70 Adenocarcinoma w/mucinous
PDCCE 6th 25 65 10 60 Adenocarcinoma w/mucinous
PDCCE 10th 35 50 15 80 Adenocarcinoma w/mucinous
CRC057 Patient 25 45 20 80 Adenocarcinoma, NOS
PDCCE 1st 40 60 0 80 Adenocarcinoma, NOS
PDCCE 5th 50 35 15 80 Adenocarcinoma, NOS
CRC066 Patient 25 45 30 80 Adenocarcinoma, NOS
PDCCE 1st 20 5 75 50 Adenocarcinoma, NOS
CRC075 Patient 35 30 25 90 Adenocarcinoma, NOS
PDCCE 1st 50 15 35 95 Adenocarcinoma, NOS
PDCCE 5th 85 5 10 75 Adenocarcinoma, NOS
PDCCE 11th 65 10 25 70 Adenocarcinoma, NOS
CRC093 Patient 15 30 55 60 Adenocarcinoma, NOS
PDCCE 1st 65 30 5 80 Adenocarcinoma, NOS
PDCCE 5th 80 10 10 85 Adenocarcinoma, NOS
CRC096 Patient 20 65 15 65 Adenocarcinoma, NOS
PDCCE 14th 65 30 5 90 Adenocarcinoma, NOS
CRC102 Patient 10 70 20 60 Adenocarcinoma, NOS
PDCCE 1st 80 3 17 80 Adenocarcinoma, NOS
CRC103 Patient 5 40 55 100 Adenocarcinoma, NOS
PDCCE 1st 10 90 0 95 Adenocarcinoma, NOS
PDCCE 6th 10 90 0 95 Adenocarcinoma, NOS
CRC120 Patient 35 0 65 50 Adenocarcinoma w/signet ring & mucinous
PDCCE 1st 85 0 15 70 Adenocarcinoma w/signet ring
CRC133 Patient 65 10 15 90 Adenocarcinoma, NOS
PDCCE 7th 10 85 5 80 Adenocarcinoma, NOS
CRC149 Patient 25 60 15 80 Adenocarcinoma, NOS
PDCCE 1st 40 55 5 70 Adenocarcinoma, NOS
CRC170 Patient 10 40 50 90 Adenocarcinoma, NOS
PDCCE 2nd 80 5 15 80 Adenocarcinoma, NOS
doi:10.1371/journal.pone.0038422.t002
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cal clustering analysis was then performed on the normalized data
set and revealed three distinct clusters (Figure 3). Of the 27
matched patient tumor and PDCCEs, 22 pairs (81%) fell within
the same cluster based on the dendrogram and 18 PDCCEs (66%)
clustered directly with the original tumor sample. Altogether, these
data suggest that basic global gene-expression patterns are
preserved between PDCCEs and their original human counter-
parts.
Oncogene Mutation Status is Retained in PDCCEs
For patients with advanced colorectal cancer, the testing of
mutation status of oncogenes such as KRAS is required for guiding
therapy. Specifically, patients with KRAS mutations show no
benefit from treatment with EGFR inhibitors such as cetuximab or
panitumumab, while patients whose tumors are KRAS WT derive
benefit from anti-EGFR based therapies [19,20]. To determine
whether these clinically-significant genomic parameters are
maintained in PDCCEs, 27 matched PDCCEs and original
patient samples were analyzed for KRAS and BRAF mutation
status. Of the 27 matched pairs evaluated, 13 presented with
activating KRAS mutations (codon 12=11; Codon 13=2)
(Table 3). Of these 27 matched pairs, 26/27 PDCCEs (96%)
matched their original human counterpart suggesting that human
colorectal cancer tissues maintained as mouse PDCCEs are
genetically stable and retain oncogenic mutation status critical to
CRC pathophysiology. All samples tested negative for BRAF
mutations. Altogether, these data suggest that PDCCEs maintain
the biologically complex histological, gene expression and
mutation-based characteristics observed in human CRCs.
Discussion
To date, a number of mouse xenograft models have been
established to investigate CRC etiology and treatment. To a large
extent, these models have been generated using late passage cell
lines derived from human CRCs and while significant treatment-
induced tumor responses have been observed in these models, they
are rarely predictive of tumor response in human patients [7]. This
is likely due in these models, at least in part, to the inherent lack of
stroma in tumor-derived epithelial cell lines. Mounting evidence
indicates that paracrine signaling and extracellular matrix
components supplied by neighboring stromal cells play a significant
role in the oncogenic potential of colorectal carcinoma and that
modulation of these stromal interactions directly impact the
efficacy of chemotherapy on tumor response [9,10].
Recent attempts have been made to generate mouse xenograft
models of CRC by direct transplantation of human colon tumors
into immune-compromised mice [14–16,21]. Poupon and co-
workers reported that the passage of human colon cancer tissues
through a xenograft stage significantly improves the success rate of
cell line derivation from human CRC metastases [15]. More
recently, Hohenadl and coworkers reported that histological
characteristics and oncogene expression levels are retained in
early passage CRC xenografts [21] while Fichtner et al., and
Messersmith et al, used panels of 15- and 10 human CRC explants
respectively to evaluate drug sensitivity [14,16]. Additionally, these
studies used patient-derived explants mainly from the primary site
and as metastatic tumors tend to be more aggressive and are more
likely to differentiate, it remains unclear if PDCCEs generated
from metastatic sites would maintain similarity to the original
Figure 2. PDCCEs retain nuclear CDX2 expression and signet ring morphology observed in original patient tumors. A. Representative
PDCCE (CRC039) retains nuclear CDX2 expression after 11 generations in mice. Images shown are at 206magnification. B. Early passage PDCCEs
retain signet ring morphology observed in original patient colorectal tumor. Images shown are at 406magnification. C. Xenografts generated from
WiDr and HT29 CRC cell lines lack histological features consistent with patient-derived explants including the presence of stroma and the formation
of glands. Images shown are at 206magnification.
doi:10.1371/journal.pone.0038422.g002
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explant models in CRC research, a more comprehensive
histological and molecular analysis on a larger panel of human
CRC explants are needed to justify their use as a preclinical model
to perform accurate drug efficacy analysis and predictive bio-
marker identification.
In this study, we demonstrate that PDCCEs generated from
human adenocarcinomas with varying histological features each
retain the parameters of the tumor from which they were derived at
the histological, global RNA expression and oncogene mutation
levels.Despitetheexistenceofdifferencesinthepercentageoftumor
stroma present between the original human tissues and those
xenografted intomice, our study focuses on the malignant epithelial
cells. First, the histological architecture inherent to colorectal
adenocarcinoma, primarily the ability to form dysplastic glands as
well as the presence of CDX-2 positive nuclei is maintained in the
PDCCEs throughout multiple passages (.10). Next, we compared
the gene expression profiles between matched PDCCEs and its
corresponding patient tumor and observed that 18/27 (66%) of the
samples clustered directly together and 22/27 (81%) clustered
within the major cluster as defined by the dendrogram.
We speculate that the 9 PDCCE samples that did not cluster
directly with their corresponding original tumor may have been
due to the inherent heterogeneous nature of CRC. It is plausible
that the original CRC tumor samples corresponding to these 9
PDCCEs harbored small sub-populations bearing additional
oncogenic events. This would in turn confer a growth advantage
to these populations after being transplanted into the mouse,
causing the PDCCE to have a different genetic composition than
the original tissue from which it was derived. In support of this
notion, it appears that most variation between the primary tumor
and its PDCCE occur in early PDCCE passages and that less
variation occurs through the process of passaging. For example,
PDCCE CRC105 clustered with the original patient sample at
PDCCE passages 1 and 11 while PDCCE CRC149 did not cluster
with its original sample at either passage 1 or 5 suggesting that
genetic changes occur predominantly in early passages and are
maintained through later passages. It is also possible, that in these
9 samples, there may have been a greater stromal contamination
resulting in a difference in their clustering pattern. These results
suggest that there are indeed intrinsic differences between the
matched patient tumor and PDCCE and extrapolations drawn
Figure 3. Patient tumor tissues and matched PDCCEs exhibit similar gene expression patterns. Unsupervised cluster analysis of 27
patient tumor-PDCCE matched pairs show that 22 pairs (81%) fell within the same cluster and 18 matched PDCCE (66%) clustered directly in pairs
with the original patient tumor (gray boxes). Sample names containing an X denote PDCCE (xenograft) samples. The number immediately following
the X indicates the generation/passage number of that particular sample.
doi:10.1371/journal.pone.0038422.g003
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findings suggest that the PDCCE model has the potential to be
used in the investigation of new therapeutic agents that target both
the malignant epithelial tumor architecture and/or stromal
component and that PDCCEs can be maintained for 10 or more
generations while retaining key histological parameters.
Finally, we evaluated the KRAS and BRAF mutation status of the
PDCCEs and showed that the status of all but one of the oncogene
mutations was retained. We observed one case (CRC020) in which
a KRAS activating mutation was present in the PDCCE but was
not detected in the original patient samples despite the fact that
these samples clustered together by unsupervised cluster analysis.
It is most likely that a small, undetectable population of KRAS
mutant cells was present in the patients tumor at the time of
surgical resection and that the growth advantage conferred by
KRAS activation allowed for subsequent expansion of KRAS
mutant cells during early PDCCE passages.
Although any single mouse model will never fully recapitulate
actual findings in patients, the use of preclinical models is
necessary and practical for the development of therapeutic agents
and biomarkers and a crucial first step in bringing these agents to
the clinic. We do realize the limitations of our model and that any
finding must undergo rigorous testing to gauge its accuracy,
reliability, and reproducibility and must also be retrospectively
validated in multiple patient samples. Nevertheless we feel that our
preclinical mouse model has the potential to be used to identify
and test novel combinations of therapeutic agents and to also
develop both predictive and prognostic biomarkers, which can
then be systematically brought forth into the clinical setting.
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